Fate Therapeutics (NASDAQ: FATE) reported Q1 EPS of ($0.30), $0.06 worse than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.63 million versus the consensus estimate of $2.37 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.